News | August 26, 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated
